Albumin Excipient Market Forecast Signals New Revenue Opportunities Through 2030
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Albumin Excipient Market Value Analysis: What Growth Is Expected Over The Forecast Period?
In recent years, the albumin excipient market has witnessed considerable expansion. By 2026, its value is projected to reach $5.47 billion, up from $5.15 billion in 2025, achieving a compound annual growth rate (CAGR) of 6.2%. This historic period of growth has been driven by several key factors: an increased need for biologics, heightened research activities focused on protein-based excipients, expansion within pharmaceutical manufacturing, wider adoption of recombinant albumin, and the development of stabilized formulations.
The albumin excipient market is anticipated to experience robust expansion over the coming years, with projections indicating a rise to $7.15 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.9%. This upward trajectory during the forecast period is driven by several factors, including the broadening of the biopharmaceutical industry, progress in protein excipient technologies, a higher incidence of chronic diseases, expanded contract manufacturing operations, and a growing number of regulatory approvals for novel drug formulations. Key developments shaping this period consist of breakthroughs in protein stabilization, improvements in excipient formulation design, more sophisticated drug delivery mechanisms, adherence to regulatory standards and good manufacturing practices (GMP), and enhancements in supply chain efficiency.
Download A Free Sample Report For Comprehensive Market Insights:
Albumin Excipient Market Demand Drivers Creating New Revenue Opportunities
The increasing frequency of chronic illnesses is set to drive forward the expansion of the albumin excipient market in the coming period. A chronic illness refers to a medical condition persisting for three months or longer, which may worsen over time. Albumin serves as a blood volume expander and represents the most plentiful circulating protein found in plasma. It functions as an adaptable protein carrier aimed at drug targeting and enhancing the pharmacokinetic characteristics of peptide- or protein-based therapeutics, contributing to the management of various conditions such as cancer and diabetes. As an example, the World Health Organization, a United Nations agency based in Switzerland, reported in February 2024 that projections indicate over 35 million new cancer diagnoses will occur by 2050, reflecting a 77 percent rise from the estimated 20 million cases recorded in 2022. Consequently, the growing incidence of chronic diseases is fueling the advancement of the albumin excipient market.
Albumin Excipient Market Segment Landscape And Growth Potential
The albumin excipient market covered in this report is segmented –
1) By Product: Human Serum Albumin, Recombinant Albumin
2) By End-Users: Pharmaceutical And Biotechnology Industry, Research Institutes, Other End Users
3) By Application Type: Injectable Formulations, Vaccine Formulations, Cell Culture Or Bioprocessing, Diagnostic Formulations
Subsegments:
1) By Human Serum Albumin: 5% Human Serum Albumin, 20% Human Serum Albumin
2) By Recombinant Albumin: Recombinant Human Serum Albumin, Recombinant Bovine Serum Albumin
Albumin Excipient Market Trends Driving Strategic Industry Expansion
Key players in the albumin excipient market are increasingly turning to strategic partnerships as a means to support critical biotechnology and pharmaceutical sectors. Such collaborations involve companies capitalizing on each other’s strengths and resources to pursue shared goals and success. A demonstration of this occurred in October 2023 when ARTES Biotechnology GmbH, a German biotechnology firm, joined forces with Basic Pharma, a pharmaceutical company based in the Netherlands, to enhance recombinant protein production. Through this alliance, the objective is to improve pharmaceutical recombinant protein manufacturing by optimizing the supply chain and shortening the timeline required to bring new products to market.
Albumin Excipient Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the albumin excipient market are Albumin Therapeutics LLC, Biotest AG, CSL Behring, Grifols S.A., InVitria Inc., Octapharma AG, Kedrion Biopharma, LFB USA Inc., Baxter International Inc., Merck KGaA, Albumedix A/S, Bio Products Laboratory Ltd., Ventria Bioscience Inc., Novartis AG, China Biologic Products Holdings Inc., ProMetic Life Sciences Inc., Sanquin, Takeda Pharmaceutical Company Limited, FUJIFILM Irvine Scientific Inc., Shire Plc, Biopharma, Hualan Biological Engineering Inc., Shanghai RAAS Blood Products Co. Ltd.
Access The Complete Albumin Excipient Market Report:
Albumin Excipient Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the Albumin Excipient market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global albumin excipient market report during the forecast period. The regions covered in the albumin excipient market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
